Skip to main content
SpringerLink
Log in

Adverse Effects of Antipsychotic Drugs

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Since the introduction of chlorpromazine in the 1950s, neuroleptic medications have been the mainstay of treatment of schizophrenia and other psychotic disorders. These medications do not always lead to complete remission of symptoms but they have allowed many patients to lead more productive and satisfying lives away from the restrictions of chronic hospitalisation. However, neuroleptics are associated with a number of adverse effects that can compromise their effectiveness. Extrapyramidal adverse effects include acute dystonic reactions, neuroleptic-induced Parkinsonism and akathisia. They can often be treated with neuroleptic dose reduction, addition of anticholinergic or β-blocking agents, or medication change. Later-onset movement disorders such as tardive dyskinesia or dystonia require careful evaluation and may be treated with dose reduction or change of neuroleptic to an atypical agent. Potentially fatal reactions such as agranulocytosis and neuroleptic malignant syndrome can rarely occur and often require significant medical intervention. Clozapine offers some advantages over ‘typical’ neuroleptics but has a unique adverse effect profile which includes agranulocytosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Adler LA, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. Journal of Clinical Psychopharmacology 5: 164–166, 1985

    Article  PubMed  CAS  Google Scholar 

  • Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology 97: 1–11, 1989

    Article  PubMed  CAS  Google Scholar 

  • Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry 52: 102–104, 1991

    PubMed  CAS  Google Scholar 

  • Ayd FJ. A survey of drug induced extrapyramidal reactions. Journal of the American Medical Association 175: 1054–1060, 1961

    Article  PubMed  CAS  Google Scholar 

  • Barnes TRE, Braude WM. Tardive dyskinesia: a 3 year follow-up study. Psychological Medicine 13: 71–81, 1983

    Article  PubMed  CAS  Google Scholar 

  • Bernstein J. Antipsychotic drugs. In Bernstein (Ed.) Drug therapy in psychiatry, 2nd ed., pp. 79–122, PSG Publishing Co. Inc., Littleton, 1988

    Google Scholar 

  • Borison RL. Amantadine in the management of extrapyramidal side effects. Clinical Neuropharmacology 6(Suppl. 1): 57–63, 1983

    Article  Google Scholar 

  • Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. Journal of Clinical Psychopharmacology 7: 164–166, 1987

    PubMed  CAS  Google Scholar 

  • Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia. British Journal of Psychiatry 143: 139–150, 1983

    Article  PubMed  CAS  Google Scholar 

  • Casey DE. Tardive dyskinesia. In Meltzer (Ed.) Psychopharmacology the third generation of progress, pp. 1411–1419, Raven Press, New York, 1987

    Google Scholar 

  • Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99: S47–S53, 1989

    Article  PubMed  Google Scholar 

  • Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 4: 109–120, 1991

    Article  PubMed  CAS  Google Scholar 

  • Chakos MH, Mayerhoff DI, Loebel AD, Alvir JMJ, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacology Bulletin 28: 81–86, 1992

    PubMed  CAS  Google Scholar 

  • Daouda P, Delacour JL. Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 2: 217, 1982

    Article  Google Scholar 

  • DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52: 105–107, 1991

    PubMed  CAS  Google Scholar 

  • Dickey W. The neuroleptic malignant syndrome. Progress in Neurobiology 36: 425–436, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ducomb L, Baldessarini RJ. Timing and risk of bone marrow depression by psychotropic drugs. American Journal of Psychiatry 134: 1294–1295, 1977

    PubMed  CAS  Google Scholar 

  • Fink M, Irwin P, Weinhold P. EEG profile studies of clozapine in volunteers and psychiatric patients. Pharmakopsychiatrie 12: 184–190,1979

    Article  CAS  Google Scholar 

  • Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scandinavica 77: 369–378, 1988

    Article  PubMed  CAS  Google Scholar 

  • Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, et al. Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. Annals of Neurology 14: 89–90, 1983

    Article  PubMed  CAS  Google Scholar 

  • Granner MA, Wooten GF. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Seminars in Neurology 11: 228–235, 1991

    Article  PubMed  CAS  Google Scholar 

  • Grohmann R, Ruther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 99: S101–S104, 1989

    Article  PubMed  Google Scholar 

  • Guze BH, Baxter LR. Current concepts: neuroleptic malignant syndrome. New England Journal of Medicine 313: 163–166, 1985

    Article  PubMed  CAS  Google Scholar 

  • Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: two decades of experience. Archives of General Psychiatry 39: 803–816, 1982

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Honigfeld G, Singer J, Meitzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789–796, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B, et al. Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacology Bulletin 20a: 387–389, 1984

    Google Scholar 

  • Kaufman DM. Clinical neurology for psychiatrists, 2nd ed., Grune and Stratton Inc., Orlando, 1985

    Google Scholar 

  • Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Archives of General Psychiatry 46: 914–918, 1989

    Article  PubMed  Google Scholar 

  • Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 40: 1113–1117, 1983

    Article  PubMed  CAS  Google Scholar 

  • Koukkou M, Angst J, Zimmer D. Paroxysmal EEG activity and psychopathology during the treatment with clozapine. Pharmakopsychiatrie 12: 173–183, 1979

    Article  CAS  Google Scholar 

  • Krupp P and Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99: S118–S121, 1989

    Article  PubMed  Google Scholar 

  • Levinson DF. Pharmacologic treatment of schizophrenia. Clinical Therapeutics 13: 326–352, 1991

    PubMed  CAS  Google Scholar 

  • Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Archives of General Psychiatry 47: 761–768, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly 63: 51–70,1992

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacology Bulletin 25: 57–62, 1989

    PubMed  CAS  Google Scholar 

  • Lipinski JF, Zubenko GS, Barriera P, Cohen BM. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 2: 685–686,1983

    Article  PubMed  CAS  Google Scholar 

  • Lipinski JF, Zubenko GS, Cohen BM, Barreira PJ. Propranolol in the treatment of neuroleptic-induced akathisia. American Journal of Psychiatry 141: 412–415, 1984

    PubMed  Google Scholar 

  • McCarron MM, Boettger ML, Peck JJ. A case of neuroleptic malignant syndrome successfully treated with amantadine. Journal of Clinical Psychiatry 43: 381–382, 1982

    PubMed  CAS  Google Scholar 

  • McEvoy JP, Schooler NR, Wilson WM. Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin 27: 97–101, 1991

    PubMed  CAS  Google Scholar 

  • Miller DM, Sharafuddin MJA, Kathol RG. A case of clozapine-induced neuroleptic malignant syndrome. Journal of Clinical Psychiatry 52: 99–101, 1991

    PubMed  CAS  Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — a retrospective study of 387 patients. Psychopharmacology 99: S73–S76, 1989

    Article  PubMed  Google Scholar 

  • Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. American Journal of Psychiatry 137:1518–1522, 1980

    PubMed  CAS  Google Scholar 

  • Pickar D. Pharmacotherapeutic approaches to schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989

  • Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Archives of General Psychiatry 49: 345–353, 1992

    Article  PubMed  CAS  Google Scholar 

  • Pickar D, Owen RR, Litman RE. New developments in the pharmacotherapy of schizophrenia. Presented at Psychopharmacology in Practice: Clinical and Research Update 1991, Bethesda, Maryland, November 8–9, 1991

  • Rifkin A, Siris S. Drug treatment of acute schizophrenia. In Meitzer (Ed.) Psychopharmacology: the third generation of progress, pp. 1095–1101, Raven Press, New York, 1987

    Google Scholar 

  • Rosebush PI, Stewart TD. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. American Journal of Psychiatry 146: 717–725, 1989

    PubMed  CAS  Google Scholar 

  • Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry 50: 295–298, 1989

    PubMed  CAS  Google Scholar 

  • Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Archives of Internal Medicine 149: 1927–1931, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sachdev P. Clinical characteristics of 15 patients with tardive dystonia. American Journal of Psychiatry 150: 498–500, 1993

    PubMed  CAS  Google Scholar 

  • Safferman AZ, Lieberman JA, Alvir NMJ, Howard A. Rechallenge in clozapine-induced agranulocytosis. Lancet 339: 1296–1297, 1992

    Article  PubMed  CAS  Google Scholar 

  • Shalev A, Hermesh H, Munitz H. The role of external heat load in triggering the neuroleptic malignant syndrome. American Journal of Psychiatry 145: 110–111, 1988

    PubMed  CAS  Google Scholar 

  • Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavia 73: 337–347,1986

    Article  CAS  Google Scholar 

  • Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. Acute dystonia during fixed dose neuroleptic treatment. Journal of Clinical Psychopharmacology 10: 389–396, 1990

    Article  PubMed  CAS  Google Scholar 

  • Slack T, Stoudemire A. Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome. General Hospital Psychiatry 11: 365–367, 1989

    Article  PubMed  CAS  Google Scholar 

  • Snyder SH. Receptors, neurotransmitters and drug responses. New England Journal of Medicine 300: 465–472, 1979

    Article  PubMed  CAS  Google Scholar 

  • Van Putten T. Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry 31: 67–72, 1974

    Article  PubMed  Google Scholar 

  • Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 41: 1036–1039, 1984

    Article  PubMed  Google Scholar 

  • Wyatt RJ. Untoward effects of neuroleptic treatment. Presented at Psychopharmacology in Practice: Clinical and Research Update 1989, Bethesda, Maryland, November 3–4, 1989

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics Branch, National Institute of Mental Health, NIH Bldg 10/4N214, 9000 Rockville Pike, Bethesda, MD, 20892, USA

    Anil K. Malhotra, Robert E. Litman & David Pickar

Authors
  1. Anil K. Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Litman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Pickar
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malhotra, A.K., Litman, R.E. & Pickar, D. Adverse Effects of Antipsychotic Drugs. Drug-Safety 9, 429–436 (1993). https://doi.org/10.2165/00002018-199309060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199309060-00005

Keywords

Search

Navigation